{
  "image_filename": "table_p2_det_1_019.png",
  "image_path": "FlublokPI/extracted/figures/table_p2_det_1_019.png",
  "image_type": "Table",
  "page_number": 2,
  "block_id": "det_1_019",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": false,
  "explanation": "A table showing percentages of solicited adverse events (Any, Moderate, Severe) reported in multiple studies, with footnotes referencing Studies 2 and 4 and U.S.-licensed trivalent influenza vaccines and clinical trial registration information. does not support the claim since the table does not identify Flublok quadrivalent or Fluarix quadrivalent or any direct comparison between those two vaccines Note: Portion of the table is visible but product names and vaccine types are not shown; context is limited",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table showing percentages of solicited adverse events (Any, Moderate, Severe) reported in multiple studies, with footnotes referencing Studies 2 and 4 and U.S.-licensed trivalent influenza vaccines and clinical trial registration information.",
    "evidence_found": null,
    "reasoning": "does not support the claim since the table does not identify Flublok quadrivalent or Fluarix quadrivalent or any direct comparison between those two vaccines",
    "confidence_notes": "Portion of the table is visible but product names and vaccine types are not shown; context is limited"
  }
}